Toldefine 4% Injection

Toldefine 4% Injection


10ml of sterile aqueous solution containing 4.0% w/v tolfenamic acid as active ingredient and 1.04% benzyl alcohol as preservative.


Tolfenamic acid is a non steroidal anti-inflammatory drug (NSAID) belonging to the fenamate family. Its active principle, tolfenamic acid, plays a double role on prostaglandins: inhibition of prostaglandin synthesis from arachidonic acid and inhibition tissue response to prostaglandin by occupation of receptor sites. A single i/m or s/c injection of 4mg/kg of tolfenamic acid results in an effective serum level concentration (>0.1mcg/ml) that is maintained for 24 to 48 hours depending on the animals. The existence of an enterohepatic cycle has been shown.

Toldefine 4% Injection Indications:


Cats and Dogs: Treatment of acute and chronic inflammatory conditions. Analgesic and antipyretic.


Do not use in animals receiving corticosteroids or other NSAID’s. Do not use in animals suffering from cardiac, hepatic or renal disease, where there is evidence of blood dyscrasia. Avoid use in dehydrated, hypovolaemic or hypotensive animals as there is a potential risk of increased renal toxicity.

Special Precautions:

Use in animals under 6 weeks of age or in aged animals may involve additional risk. If such a use cannot be avoided, animals may require a reduced dosage and careful clinical management.

Toldefine 4% Injection Dosage:

The recommended dosage of Tolfedine® 4% (40mg/ml) is 1ml per 10kg b.w. (equivalent to 4mg tolfenamic acid per kg) by s/c or i/m injection. Tolfedine tablets may be used as an alternative to Tolfedine® 4% injection followed 24 – 48 hours later by Tolfedine® tablets for up to 3 days. Enterohepatic circulation of tolfenamic acid has been demonstrated and may account for its prolonged activity in cats and dogs. For long-term usage treat with tablets for 3 days per week.

Registered pursuant to the ACVM Act 1997, No A7407


Tolfedine 4% – For Animal Treatment Only

Leave a Reply

Your email address will not be published. Required fields are marked *